Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMB87M3)

Drug Name
AZD9668 Drug Info
Synonyms
Alvelestat; 848141-11-7; AZD9668; Alvelestat (AZD9668); AZD 9668; CHEMBL3617964; AZD-9668; KB-105160; Avelestat; 6-Methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide; 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-((5-(methylsulfonyl)pyridin-2-yl)methyl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide
Indication
Disease Entry ICD 11 Status REF
Bronchiectasis CA24 Phase 2 [1]
Chronic obstructive pulmonary disease CA22 Phase 2 [2]
Cross-matching ID
PubChem CID
46861623
CAS Number
CAS 848141-11-7
TTD Drug ID
DMB87M3

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Neutrophil elastase (NE) TTPLTSQ ELNE_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Neutrophil elastase (NE) DTT ELANE 2.379 2.036 1.379 2.945
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Bronchiectasis
ICD Disease Classification CA24
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Neutrophil elastase (NE) DTT ELANE 7.82E-01 0.09 0.3
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00769119) A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis (NEPAL). U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT00703391) A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of AstraZeneca (2009).